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ABSTRACT 
Background: In addition to the established association between general obesity and breast 
cancer risk, central obesity and circulating fasting insulin and glucose have been linked to the 
development of this common malignancy. Findings from previous studies, however, have been 
inconsistent, and the nature of the associations is unclear. 
Methods: We conducted Mendelian randomization analyses to evaluate the association of 
breast cancer risk, using genetic instruments, with fasting insulin, fasting glucose, 2-hour 
glucose, body mass index (BMI), and BMI-adjusted waist-hip-ratio (WHRadj BMI). We first 
confirmed the association of these instruments with type 2 diabetes risk in a large diabetes 
genome-wide association study consortium. We then investigated their associations with breast 
cancer risk using individual-level data obtained from 98 842 cases and 83 464 controls of 
European descent in the Breast Cancer Association Consortium.  
Results: All sets of instruments were associated with risk of type 2 diabetes. Associations with 
breast cancer risk were found for genetically predicted fasting insulin [odds ratio (OR)=1.71 per 
standard deviation (SD) increase, 95% CI=1.26-2.31, p=5.09×10-4], 2-hour glucose (OR=1.80 
per SD increase, 95% CI=1.30-2.49, p=4.02×10-4), BMI (OR=0.70 per 5-unit increase, 95% 
CI=0.65-0.76, p=5.05×10-19), and WHRadj BMI (OR=0.85, 95% CI=0.79-0.91, p=9.22×10
-6). 
Stratified analyses showed that genetically predicted fasting insulin was more closely related to 
risk of ER-positive cancer, while the associations with instruments of 2-hour glucose, BMI, and 
WHRadj BMI were consistent regardless of age, menopausal status, estrogen receptor status, and 
family history of breast cancer.  
Conclusions: We confirmed the previously reported inverse association of genetically predicted 
BMI with breast cancer risk and showed a positive association of genetically predicted fasting 
insulin and 2-hour glucose, and an inverse association of WHRadj BMI with breast cancer risk. Our 
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study suggests that genetically determined obesity and glucose/insulin-related traits have an 
important role in the etiology of breast cancer.  
Key words: breast cancer; insulin; glucose; obesity; genetics; Mendelian randomization 
analysis 
 
Key messages 
 Mendelian randomization studies eliminate potential influence of reverse causation on study 
results and are less susceptible to bias and confounding than conventional observational 
studies. We utilized this approach to evaluate the association of obesity and glucose/insulin-
related traits with breast cancer risk using the data of a large consortium.  
 
 We found genetically predicted fasting insulin and 2-hour glucose levels were positively 
associated with breast cancer risk, while genetically predicted body mass index and waist-
hip-ratio with adjustment of BMI were inversely associated with the risk.  
 
 Our study has uncovered complex inter-relations of genetics, obesity and breast cancer risk 
and provided novel findings regarding roles of circulating glucose and insulin in the risk of 
this common cancer.   
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Introduction 
 
 General and central obesity have been linked to breast cancer risk in previous studies. 
1,2 Body mass index (BMI) and waist-hip-ratio (WHR) are commonly used to measure general 
and central obesity, respectively. Obesity, particularly central obesity, is a major risk factor for 
insulin resistance and type 2 diabetes, which are often characterized by elevated fasting insulin 
and glucose as well as impaired glucose tolerance (usually measured by blood glucose level 2 
hours after oral glucose challenge). 3 Previous studies have linked fasting insulin and glucose 
levels to increased risks of multiple cancers. 4–6 Proposed mechanisms for these associations 
include cancer-promoting effects mediated by insulin and insulin-like growth factor (IGF) 
signaling pathways. 7 However, the relationship between these biomarkers and breast cancer 
remains controversial and findings from epidemiological studies are inconsistent. 8,9 Concerns 
regarding the validity of these observational study findings include potential selection biases, 
reverse causation, confounding effects, small sample size, and differences in assays used to 
measure the biomarkers of interest. 
Mendelian randomization analysis has been used to evaluate potential causal 
relationships between exposures and the disease. 10,11 Genetic variants are used as 
instrumental variables in the analysis. Random assortment of alleles at the time of gamete 
formation results in a random assignment of exposures that are related to an allele (or a set of 
alleles). Thus, Mendelian randomization analyses may reduce potential biases that would afflict 
conventional observational studies. In the current study, we performed Mendelian randomization 
analyses to assess associations of obesity (i.e. BMI and WHR) and glucose/insulin-related traits 
(i.e. fasting glucose, 2-hour glucose, and fasting insulin) with breast cancer risk using data from 
the Breast Cancer Association Consortium (BCAC).  
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Methods  
 
Study Population 
Included in this analysis are 182 306 participants of European ancestry whose samples 
were genotyped using custom Illumina iSelect genotyping arrays, OncoArray (56 762 cases and 
43 207 controls) or iCOGS array (42 080 cases and 40 257 controls). Institutional review boards 
of all involved institutes approved the studies. Selected characteristics of the two datasets are 
presented in Supplementary Table 1. Details of the genotyping protocols in the BCAC are 
described elsewhere (iCOGS: http://ccge.medschl.cam.ac.uk/research/consortia/icogs/; 
OncoArray: https://epi.grants.cancer.gov/oncoarray/). 12,13 Genotyping data were imputed using 
the program IMPUTE2 14 with the 1000 Genomes Project Phase III integrated variant set as the 
reference panel. SNPs with low imputation quality (imputation r2 < 0.5) were excluded. Top 
principal components (PCs) were included as covariates in regression analysis to address 
potential population substructure (iCOGS: top eight PCs; OncoArray: top 15 PCs). 
 
Selection of SNPs associated with glucose/insulin-related traits  
In December 2016, we searched the National Human Genome Research Institute-
European Bioinformatics Institute Catalog of Published Genome-Wide Association Studies and 
the literature for SNPs associated with the following traits: levels of 2-hour glucose (2hrGlu), 
fasting glucose (FG), fasting insulin (FI), BMI, and waist-hip-ratio with adjustment of BMI 
(WHRadj BMI). 
15–19 SNPs associated with any of these traits at the genome-wide significance 
level (p<5×10-8) in populations of European ancestry were included. For each GWAS-identified 
locus, a representative SNP with the lowest p value in the original GWAS publication was 
selected (linkage disequilibrium r2<0.1, based on 1000 Genome Phase III CEU data).  
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Construction of instrumental variables 
Weighted polygenic scores for each trait (ie. wPRS-2hrGlu, wPRS-FG, wPRS-FI, wPRS-
BMI, and wPRS-WHRadj BMI) were constructed followed the formula: wPRS = ∑ 𝛽𝑖,𝐺𝑋 ∗ 𝑆𝑁𝑃𝑖𝑖 , 
where βi, GX is the beta coefficient of the i 
th SNP for the trait of interest from the published 
GWAS (Supplementary Table 2). SNPi is the imputed dosage of the effect allele in BCAC data 
(range: 0 to 2). To reduce potential pleiotropic effects, we excluded BMI and WHRadj BMI -
associated SNPs from instruments of 2hrGlu, fasting glucose and insulin (r2<0.8), and vice 
versa. The pleiotropic SNPs associated with more than one trait were presented in 
Supplementary Table 2. The F-statistic was taken to indicate whether an instrumental variable is 
well-powered for Mendelian randomization analysis with 10 being a commonly used threshold. 
20 Variance explained (%) and F statistics were calculated following the formulae:  ∑ 2 ∗𝑖 𝛽𝑖,𝐺𝑋
2 ∗
𝑓𝑒𝑓𝑓𝑒𝑐𝑡 𝑎𝑙𝑙𝑒𝑙𝑒 ∗
(1−𝑓𝑒𝑓𝑓𝑒𝑐𝑡 𝑎𝑙𝑙𝑒𝑙𝑒)
𝑣𝑎𝑟(𝑋)
∗ 100 and R2 *(n-1-k)/(1-R2)/k, respectively, where R2 is percentage 
of variance explained by used SNPs; f is the frequency of the effect allele reported by GWAS for 
the trait; var(X) is the variance of trait, see below; n is the sample size of BCAC data; and k is 
the number of SNPs used in the instrument. 21 
For 2-hour glucose, fasting glucose and insulin, βi, GX were further transformed to 
represent 1 standard deviation (SD) increase with the unit in the original GWAS (2-hour glucose: 
1 SD= 2 mmol/L, variance= 4; fasting glucose: 1 SD= 0.65 mmol/L, variance= 0.42; fasting 
insulin: 1 SD= 0.60 ln[pmol/L], variance= 0.36) 17,22 by the formula: βi ,SD =βi, GX [2*f (SNPi)(1-f 
(SNPi)]^0.5/SD. wPRS-BMI and wPRS-WHRadj BMI represented the adjusted 1-SD increase of 
transformed BMI and WHRadj BMI as the original GWAS performed the inverse normal 
transformation for both phenotypes. 18,19,23 We further scaled wPRS-BMI to be equivalent to 5 
units of BMI by performing a linear regression among controls in our dataset: observed BMI ~ 
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wPRS-BMI+error. Then we calculated the transformed BMI as BMIwPRS=β0 + β1* (wPRS-BMI), 
where β0 and β1 are slope and coefficient from the linear regression model mentioned above.  
 
Statistical analysis 
Given an established association between impaired glucose/insulin traits and type 2 
diabetes, an association between constructed instruments and risk of type 2 diabetes are 
expected. We utilized summary statistics from the DIAbetes Genetics Replication And Meta-
analysis (DIAGRAM) Consortium and conducted an Mendelian randomization analysis of our 
traits using the inverse-variance-weighted two-sample method 10,24. The Mendelian 
randomization estimate and standard error were calculated as ∑ 𝛽𝑖,𝐺𝑋𝑖 ∗ 𝛽𝑖,𝐺𝑌 ∗ 𝜎𝑖,𝐺𝑌
−2 /(∑ 𝛽𝑖,𝐺𝑋
2
𝑖 ∗
𝜎𝑖,𝐺𝑌
−2 ) and 1/(∑ 𝛽𝑖,𝐺𝑋
2
𝑖 ∗ 𝜎𝑖,𝐺𝑌
−2 )0.5, respectively. GY represents the association between a SNP 
and type 2 diabetes risk, thus βi, GY and σi, GY are beta coefficient and standard error, respectively. 
The p value was based on Student’s t distribution, where the degrees of freedom were 
determined by the number of SNPs included in the instrument for the trait of interest. We 
calculated Pearson’s correlations between each pair of wPRSs in the control data before and 
after removal of pleiotropic SNPs. Egger’s regression, as described in Bowden et al, 25 was 
performed to detect potential pleiotropy of our instruments. We also included all instruments in 
the same model to evaluate possible independent associations of each instrument with breast 
cancer risk.  
Associations of wPRSs with breast cancer risk were evaluated separately in the iCOGs 
and OncoArray datasets by treating these scores as continuous variables. A logistic regression 
was performed with age at interview/diagnosis, study site/country, and PCs as covariates. The 
results were then combined using meta-analyses in METAL with a fixed-effects model. 26 We 
performed additional analyses adjusting for certain known breast cancer risk factors listed in 
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Supplementary Table 1. Finally, we conducted sub-analyses by estrogen receptor (ER) status, 
age at interview/diagnosis (<50 versus ≥50), menopausal status at interview/breast cancer 
diagnosis, and family history of breast cancer. All statistical analyses were conducted using R 
statistical software (version 3.1.2). 
 
Results 
 
Approximately 90% of cases included in this study were diagnosed at age 40 or above. 
A total of 278 SNPs were selected to construct the instruments, for which the number of SNPs 
for each trait ranged from 4 to 166 (Table 1). The variance of each trait explained by its 
associated variants ranged from 0.23% for 2-hour glucose to 2.89% for BMI (Table 1). (Table 1 
here) 
Using data from DIAGRAM, we demonstrated that all genetic instruments were 
associated with risk of type 2 diabetes in the direction that would be expected (Table 2). The 
strongest association was observed for the genetic instrument for fasting glucose (OR=6.37, 
p=5.77×10-16 and OR=4.32, p=1.12×10-11 before and after the exclusion of pleiotropic SNPs, 
respectively). (Table 2 here) 
We observed associations of breast cancer risk with genetically predicted 2-hour 
glucose, BMI, and WHRadj BMI prior to the removal of pleiotropic SNPs (Table 3). Removing 
pleiotropic SNPs did not appreciably change the associations. A one-SD increase in genetically 
predicted 2-hour glucose levels was associated with an 80% increased risk of breast cancer 
(OR=1.80, 95% CI=1.30-2.49, p=4.02×10-4). An inverse association was observed for both 
genetically predicted BMI and WHRadj BMI (per 5 units of BMI increase: OR=0.70, 95% CI=0.66-
0.77, p=5.05×10-19; per unit increase of genetic risk score for WHRadj BMI: OR=0.85, 95% CI= 
0.79-0.91, p=9.22×10-6). The association of breast cancer risk with genetically predicted fasting 
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insulin became significant after excluding pleiotropic SNPs (OR=1.71, 95% CI= 1.26-2.31, 
p=5.09×10-4). No association was observed for genetically predicted fasting glucose. Results of 
iCOGS and OncoArray were shown separately in Supplementary Table 3. (Table 3 here) 
 Genetically predicted fasting insulin was correlated with both genetically predicted 2-
hour glucose and WHRadj BMI (Supplementary Table 4). Exclusion of pleiotropic SNPs attenuated 
these correlations. Mutual adjustment of all instruments did not materially change the observed 
associations with breast cancer risk described above (Supplementary Table 5). We evaluated 
the associations of genetically predicted obesity and glucose/insulin-related traits with traditional 
risk factors for breast cancer and found that genetically predicted fasting insulin and WHRadj BMI 
were associated with BMI in controls. Further, genetically predicted BMI were correlated with 
age at menarche, age at first live birth, and breast feeding history (Supplementary Table 6). 
Adjusting for these covariates did not materially change the observed associations of genetically 
predicted fasting insulin, BMI, and WHRadjBMI with breast cancer risk (Supplementary Table 7). 
Finally, using Egger’s regression, we found that the intercept in the model was noticeable for 
genetically predicted 2-hour glucose, BMI, and WHRadj BMI, indicating a strong pleiotropic effect 
for these instruments (p<0.005 for β0, Supplementary Table 8). 
25 No apparent pleiotropy was 
found for genetically predicted fasting insulin. The Mendelian randomization estimates from 
Egger’s regression remained significant after accounting for detected pleiotropy for genetically 
predicted BMI and WHRadj BMI (Supplementary Table 8).  
Stratified analysis was performed by age, menopausal status, ER status, and family 
history of breast cancer. Genetically predicted 2-hour glucose, BMI, and WHRadj BMI were 
consistently associated with breast cancer across all strata (Figure 1-A, C, D, P het>0.05, 
exclusion of pleiotropic SNPs). The results of stratified analysis are shown for other sets of 
instrumental variables in Supplementary Figures 1 (inclusion of pleiotropic SNPs) and 2 (fasting 
glucose, exclusion of pleiotropic SNPs).  
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Discussion 
In this large study we found that genetically predicted obesity, 2-hour glucose and 
fasting insulin were associated with breast cancer risk. Measured BMI has been well 
established to be positively associated with breast cancer risk in postmenopausal women but 
inversely related to the risk in premenopausal women. Results from epidemiologic studies 
investigating the association of breast cancer risk with WHR, fasting insulin and glucose have 
been inconsistent. Traditional epidemiological studies are prone to biases, including 
confounding, selection biases, recall biases and reverse causality. Mendelian randomization 
analyses take advantage of the random assignment of genetic alleles during gamete formation 
to minimize the biases commonly encountered in traditional epidemiological studies. When an 
instrumental variables are not associated with any potential confounders and are not linked to 
the outcome via any alternative pathway, Mendelian randomization analysis using such 
instrumental variables resemble randomized clinical trials and thus could provide strong results 
for causal inference for the exposure of interest .10  
We found that the risk of breast cancer increased approximately 70% for each SD 
increase of genetically predicted fasting insulin levels. Previous epidemiological studies were 
unable to reach a conclusion regarding the association between fasting insulin and breast 
cancer risk. A meta-analysis reported a null association for fasting insulin. 8 However, the I2, an 
indicator of heterogeneity across studies, was considerable. Our results provide strong evidence 
to support a positive association. Insulin is an important growth factor with cancer-promoting 
features such as stimulating cell mitosis and migration and inhibiting apoptosis. Its mitogenic 
effects involve the activation of Ras and the mitogen-activated protein kinase pathway, 27 of 
which the role in cancer development have been recognized. 28 Further, insulin may inhibit the 
production of sex hormone binding globulin and lead to elevated bioavailable estrogen levels. 29 
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It also has been shown that knockdown of insulin and IGF-1 receptors inhibits hormone 
dependent growth of ER(+) breast cancer cells. 30 It may explain the association of fasting 
insulin with ER(+) breast cancer observed in this study.  
Previous epidemiological studies have suggested that fasting glucose may be a risk 
factor for breast cancer, but few have assessed 2-hour glucose levels, as the latter is difficult to 
investigate in large prospective cohort studies. Overall, a meta-analysis of prospective studies 
showed no strong evidence to support an association of fasting glucose levels and risk of breast 
cancer in nondiabetic women. 9 In the current study, we found a positive association with breast 
cancer for genetically predicted 2-hour glucose levels but not for fasting glucose. Although 
fasting glucose and 2-hour glucose are closely correlated, 31 they represent different biological 
processes. The genetically determined fasting glucose levels primarily reflect the glycogenolysis 
activity in liver and hepatic insulin sensitivity. 32 On the other hand, the levels of post-challenge 
glucose are mainly determined by the amount and pace of insulin released into blood stream in 
response to the challenge as well as by the glucose uptake in skeletal muscle cells (in other 
words, it primarily reflects beta cell function and skeletal muscle insulin sensitivity 33). The 
reasons why genetically predicted 2-hour glucose is associated with increased risk of breast 
cancer but not fasting glucose are not clear. One animal study has provided evidence that 
transgenic mice with inactivated insulin and IGF-1 receptors in skeletal muscles (impaired 
skeletal muscle insulin sensitivity) can lead to hyperinsulinemia and an accelerated 
development of breast cancer. 34 Since genetically predicted 2-hour glucose is correlated with 
instruments for other traits, we cannot completely rule out the possibility that the association of 
2-hour glucose may be mediated by other insulin-related traits; even these traits were carefully 
adjusted and having pleiotropic SNPs excluded in our analyses. 
We reported previously that genetically predicted BMI was inversely associated with 
breast cancer risk in both pre- and post-menopausal women. 35 We have now confirmed this 
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finding with a much larger sample size and more BMI-associated SNPs. While our finding for 
pre-menopausal breast cancer is consistent with previous observational studies, the inverse 
association observed in our study between genetically predicted BMI and post-menopausal 
breast cancer risk contradict prior findings based on measured BMI. Multiple lines of evidence 
suggest that early life body size may be inversely associated with both premenopausal and 
postmenopausal breast cancer risk. 36,37 It has been speculated that reduced serum estradiol 
and progesterone levels, due to an increased frequency of anovulation, play a role. In addition, 
the association is further supported by the observation that early life fatness was inversely 
correlated with IGF-1 levels measured in later adulthood. 38 We hypothesize that genetically 
predicted BMI may be more closely correlated to early life body weight, while obesity 
determined using measured BMI later in life may be more closely related to environmental and 
lifestyle factors that are associated with breast cancer risk. Indeed, one previous study found 
that a BMI-genetic score was positively associated with weight gain before reaching middle age 
but inversely associated with weight gain after reaching middle age. 39 If the hypothesis is 
correct, our study may provide additional support for preventing weight gain later in life to 
reduce the risk of breast cancer.  
Results from previous studies regarding the association of WHR with breast cancer risk 
have been inconsistent. While several previous studies reported that measured WHR was 
associated with breast cancer risk, 40 we recently found that this association was substantially 
attenuated after adjusting for BMI using data from a large prospective cohort study conducted 
among Chinese women. 41 In the current study, we observed an inverse association between 
genetically predicted WHRadj BMI and breast cancer risk in both pre- and post-menopausal 
women. This finding was unexpected given the close association of measured WHR with type 2 
diabetes. 42 As discussed previously for the BMI findings, we hypothesize that genetically 
predicted WHRadj BMI may reflect visceral adipose tissue level in early life, while measured WHR 
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in late adulthood reflect accumulation of visceral fats later in life. Additional research is needed 
to understand the inter-relationship of genetically predicted WHR, measured WHR and breast 
cancer risk.  
We showed that genetically predicted obesity and circulating insulin and glucose levels 
were positively correlated with risk of type 2 diabetes. Epidemiologic studies have shown that a 
prior diagnosis of type 2 diabetes is related to an elevated risk of breast cancer risk, although 
the association was weak to moderate. 43 However, in a previous study, we found a null 
association between a polygenetic risk score for type 2 diabetes and breast cancer risk. 44 It is 
possible that lifestyle changes after diabetes diagnosis and/or diabetes treatment may have 
confounded this association. Given the significant association we found in this study for breast 
cancer risk with genetically predicted fasting insulin and 2-hour glucose, two factors that are 
strongly associated with type 2 diabetes risk, we suggest that type 2 diabetes may be 
associated with breast cancer risk.  
The sample size of our study is very large, providing us sufficient statistical power for 
Mendelian randomization analyses of multiple obesity and glucose/insulin-related traits with 
breast cancer risk. Our ability to perform Mendelian randomization analysis is limited by the 
genetic variants identified to date in GWAS, and the variance explained by these genetic 
variants for some traits is small. We used 10 instruments in our main analysis, which could lead 
to false-positive findings due to multiple comparisons. However, the associations reported in this 
study for 2-hour glucose, fasting insulin, BMI, and WHRadj BMI were robust, reaching the stringent 
Bonferroni corrected significance level (p<0.05/10=0.005). Pleiotropy was found for the 
associations of obesity but it is not likely that the observed associations can be primarily 
explained by pleiotropic effects. 
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In summary, this study provided new evidence that genetically predicted fasting insulin, 
2-hour glucose, BMI, and WHRadj BMI are associated with breast cancer risk in women. Further 
research into the complex association of genetics, obesity, glucose/insulin-related traits, and 
breast cancer risk will help to improve the understanding of underlying biological mechanisms 
for the associations observed in this study and provide tools to reduce breast cancer risk.  
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Figure Legend 
Figure 1. Associations of genetically predicted obesity and levels of circulating glucose 
and insulin with overall breast cancer risk: stratified analysis 
The P heterogeneity was obtained from heterogeneity test across strata.  
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